Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2866756 | 0.81 | SMN1; SMN2 (0.36) | AAK1MAPTALOX15HTTNPSR1 | |
| SCHEMBL2875445 | 0.79 | AAK1 (0.39) | AAK1GCGRTDP1HTTNPSR1 | |
| SCHEMBL2873804 | 0.79 | AAK1 (0.34) | AAK1GCGRTDP1MAPTHTT | |
| SCHEMBL2865970 | 0.78 | CACNA1H (0.33) | TDP1 | |
| SCHEMBL2868954 | 0.71 | SMN1; SMN2 (0.36) | AAK1MAPTALOX15HTTNPSR1 | |
| SCHEMBL2872949 | 0.70 | KDM4E (0.36) | AAK1MAPTHTTSMN1; SMN2 | |
| SCHEMBL2866173 | 0.70 | — | — | |
| SCHEMBL2872637 | 0.67 | AAK1 (0.36) | AAK1MAPTALOX15HTTNPSR1 | |
| SCHEMBL2873829 | 0.66 | KDM4E (0.35) | AAK1MAPTHTTSMN1; SMN2 | |
| SCHEMBL6753981 | 0.65 | AAK1 (0.45) | AAK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010103306-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIVARAL AGENTS | ASTRAZENECA UK LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |